Serum bile acids and GLP-1 decrease following telemetric induced weight loss: Results of a randomized controlled trial

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Biemann, Ronald ^a   Penner, Marina ^a   Borucki, Katrin ^a   Westphal, Sabine ^a   Luley, Claus ^a   Rönicke, Raik ^a   Biemann, Kathleen ^a   Weikert, Cornelia ^b,c   Lux, Anke ^a   Goncharenko, Nikolai ^d   Marschall, Hanns Ulrich ^e   Schneider, Jochen G ^f,g   Isermann, Berend ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d INTEGRATED BIOBANK OF LUXEMBOURG   (Luxembourg)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF LUXEMBOURG   (Luxembourg)

^g SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; GLUCAGON LIKE PEPTIDE 1; INSULIN;

BLOOD; BODY MASS; BODY WEIGHT; BODY WEIGHT LOSS; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

BILE ACIDS AND SALTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; FASTING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME; MIDDLE AGED; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 84979595881     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30173     Document Type: Article

References (47)

1. Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645, doi: 10.1161/CIRCULATIONAHA.109.192644 (2009).
2. Pierdomenico, S. D. et al. Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. American journal of hypertension 20, 1291-1296, doi: 10.1016/j.amjhyper.2007.06.011 (2007).
3. Goldberg, R. B., Mather, K. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arteriosclerosis, thrombosis, and vascular biology 32, 2077-2090, doi: 10.1161/ATVBAHA.111.241893 (2012).
4. Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752, doi: 10.1161/CIRCULATIONAHA.105.169404 (2005).
5. Haeusler, R. A., Pratt-Hyatt, M., Welch, C. L., Klaassen, C. D., Accili, D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab 15, 65-74, doi: 10.1016/j.cmet.2011.11.010 (2012).
6. Katsuma, S., Hirasawa, A., Tsujimoto, G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochemical and biophysical research communications 329, 386-390, doi: 10.1016/j.bbrc.2005.01.139 (2005).
7. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362-1365 (1999).
8. Song, K. H., Li, T., Owsley, E., Strom, S., Chiang, J. Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 49, 297-305, doi: 10.1002/hep.22627 (2009).
9. Gerhard, G. S. et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes care 36, 1859-1864, doi: 10.2337/dc12-2255 (2013).
10. Jorgensen, N. B. et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. The Journal of clinical endocrinology and metabolism 100, E396-406, doi: 10.1210/jc.2014-1658 (2015).
11. Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621-1624, doi: 10.1126/science.1198363 (2011).
12. Laferrere, B. et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes care 30, 1709-1716, doi: 10.2337/dc06-1549 (2007).
13. Patti, M. E. et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 17, 1671-1677, doi: 10.1038/oby.2009.102 (2009).
14. Werling, M. et al. Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. Scandinavian journal of gastroenterology 48, 1257-1264, doi: 10.3109/00365521.2013.833647 (2013).
15. Haeusler, R. A., Astiarraga, B., Camastra, S., Accili, D., Ferrannini, E. Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids. Diabetes 62, 4184-4191, doi: 10.2337/db13-0639 (2013).
16. Bradley, D. et al. Gastric bypass and banding equally improve insulin sensitivity and beta cell function. J Clin Invest 122, 4667-4674, doi: 10.1172/JCI64895 (2012).
17. Luley, C. et al. Weight loss by telemonitoring of nutrition and physical activity in patients with metabolic syndrome for 1 year. J Am Coll Nutr 33, 363-374, doi: 10.1080/07315724.2013.875437 (2014).
18. Luley, C., Blaik, A., Reschke, K., Klose, S., Westphal, S. Weight loss in obese patients with type 2 diabetes: effects of telemonitoring plus a diet combination-the Active Body Control (ABC) Program. Diabetes research and clinical practice 91, 286-292, doi: 10.1016/j.diabres.2010.11.020 (2011).
19. Albaugh, V. L. et al. Early Increases in Bile Acids Post Roux-en-Y Gastric Bypass Are Driven by Insulin-Sensitizing, Secondary Bile Acids. J Clin Endocrinol Metab 100, E1225-1233, doi: 10.1210/jc.2015-2467 (2015).
20. Kohli, R. et al. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab 98, E708-712, doi: 10.1210/jc.2012-3736 (2013).
21. Pournaras, D. J. et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 153, 3613-3619, doi: 10.1210/en.2011-2145 (2012).
22. Steinert, R. E. et al. Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial. Obesity (Silver Spring) 21, E660-668, doi: 10.1002/oby.20522 (2013).
23. Sjoholm, K., Sjostrom, E., Carlsson, L. M., Peltonen, M. Weight Change-Adjusted Effects of Gastric Bypass Surgery on Glucose Metabolism: 2-and 10-Year Results From the Swedish Obese Subjects (SOS) Study. Diabetes Care 39, 625-631, doi: 10.2337/dc15-1407 (2016).
24. Calkin, A. C., Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13, 213-224, doi: 10.1038/nrm3312 (2012).
25. Foretz, M. et al. ADD1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19, 3760-3768 (1999).
26. Bennion, L. J., Grundy, S. M. Effects of diabetes mellitus on cholesterol metabolism in man. The New England journal of medicine 296, 1365-1371, doi: 10.1056/NEJM197706162962401 (1977).
27. Cariou, B. et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutrition, metabolism 8, 48, doi: 10.1186/1743-7075-8-48 (2011).
28. van der Werf, S. D., van Berge Henegouwen, G. P., van den Broek, W. Estimation of bile acid pool sizes from their spillover into systemic blood. J Lipid Res 26, 168-174 (1985).
29. Fujino, T., Une, M., Imanaka, T., Inoue, K., Nishimaki-Mogami, T. Structure-activity relationship of bile acids and bile acid analogs in regard to FXR activation. Journal of lipid research 45, 132-138, doi: 10.1194/jlr.M300215-JLR200 (2004).
30. Modica, S., Gadaleta, R. M., Moschetta, A. Deciphering the nuclear bile acid receptor FXR paradigm. Nuclear receptor signaling 8, e005, doi: 10.1621/nrs.08005 (2010).
31. Duran-Sandoval, D. et al. Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes 53, 890-898 (2004).
32. Nervi, F. O., Severin, C. H., Valdivieso, V. D. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochimica et biophysica acta 529, 212-223 (1978).
33. Gafvels, M. et al. Structure and chromosomal assignment of the sterol 12alpha-hydroxylase gene (CYP8B1) in human and mouse: eukaryotic cytochrome P-450 gene devoid of introns. Genomics 56, 184-196, doi: 10.1006/geno.1998.5606 (1999).
34. Brufau, G. et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 52, 1455-1464, doi: 10.1002/hep.23831 (2010).
35. Kaur, A. et al. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes 64, 1168-1179, doi: 10.2337/db14-0716 (2015).
36. Dutia, R. et al. Temporal changes in bile acid levels and 12alpha-hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. Int J Obes (Lond) 39, 806-813, doi: 10.1038/ijo.2015.1 (2015).
37. Ridlon, J. M., Kang, D. J., Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. Journal of lipid research 47, 241-259, doi: 10.1194/jlr.R500013-JLR200 (2006).
38. Zhang, J. H. et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. American journal of physiology. Gastrointestinal and liver physiology 304, G940-948, doi: 10.1152/ajpgi.00398.2012 (2013).
39. Beysen, C. et al. Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 55, 432-442, doi: 10.1007/s00125-011-2382-3 (2012).
40. Williams, D. L., Baskin, D. G., Schwartz, M. W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 55, 3387-3393, doi: 10.2337/db06-0558 (2006).
41. Gutzwiller, J. P. et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 81-86 (1999).
42. Yamaoka-Tojo, M. et al. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovascular diabetology 9, 17, doi: 10.1186/1475-2840-9-17 (2010).
43. de Luis, D. A., Gonzalez Sagrado, M., Conde, R., Aller, R., Izaola, O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Annals of nutrition, metabolism 51, 134-138, doi: 10.1159/000103273 (2007).
44. Heijboer, A. C., Frans, A., Lomecky, M., Blankenstein, M. A. Analysis of glucagon-like peptide 1; what to measure Clin Chim Acta 412, 1191-1194, doi: 10.1016/j.cca.2011.03.010 (2011).
45. Geenes, V. et al. The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. PloS one 9, e83828, doi: 10.1371/journal.pone.0083828 (2014).
46. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412-419 (1985).
47. Wei, C., Li, J., Bumgarner, R. E. Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics 5, 87, doi: 10.1186/1471-2164-5-87 (2004).